The Lightfusion LED platform has been approved by the US Food and Drug Administration (FDA) as a Class 2 medical device for the treatment of periorbital wrinkles.
The device harnesses light energy, delivering different wavelengths of light to alter biological activity aiming to promote collagen and elastin synthesis, improve blood flow and eliminate toxins.
According to UK supplier Skinbrands, Lightfusion has been created with a modular design so it can be positioned on the face without being claustrophobic. It can also be used to treat the neck, décolleté and hands. The device can be used as a standalone treatment, as part of a course, or to complement other treatments such as mirconeedling, dermarolling, chemical peels and laser.
Amanda Coveney, managing director of UK supplier Skinbrands said of the approval, "The FDA endorsement is a significant milestone and coincides with the launch of Lightfusion in the US with distributers Silhouette Tone LLC and Refine LLC. We are hugely excited about the opportunities represented by the US launch and are developing a portfolio of products to expand the Lightfusion line for the aesthetic and medispa market."